Argireline

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Argireline is regulated as a cosmetic ingredient in the United States. Products containing it are subject to FDA oversight under the Modernization of Cosmetics Regulation Act (MoCRA, 2022), which requires facility and product registration as of July 2024, adequate safety substantiation, and compliant labelling using the INCI name. It is not FDA-approved as a drug and is not subject to Category II (FDA-19) bulk drug substance restrictions. No prescription is required for purchase or possession of cosmetic products containing argireline.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Argireline

Origin

Developed and commercialised by Lipotec (now Lubrizol Life Science) under the trade name Argireline®. The sequence is an acetylated analogue of the N-terminal domain of SNAP-25, one of the three core proteins of the neuronal SNARE complex.

Registry IDs

PubChem CID

71587772

CAS

616204-22-9

InChIKey

AJLNZWYOJAWBCR-OOPVGHQCSA-N

DrugBank

DB11709

Molecular formula

C35H62N14O11S

Molar mass

887.0 g/mol

Monoisotopic

886.44432002 Da

InChIKey

AJLNZWYOJAWBCR-OOPVGHQCSA-N

Appearance

White to off-white lyophilised powder (vendor-typical)

Solubility

Water-soluble; hydrophilic character (log P approximately -6.3); limited partiti…

Sequence not available in current seed.

Stability: Stable as lyophilised powder under cool, dry conditions. Aqueous solution stability is pH- and temperature-dependent; oxidation of methionine residue (position

Vial sizes

null mg

Purity grades

cosmetic grade / research grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Argireline mimics the N-terminal fragment of SNAP-25 and competes with endogenous SNAP-25 for incorporation into the trimeric SNARE complex (VAMP/Syntaxin/SNAP-25)
• This competitive interference destabilises SNARE complex assembly without irreversibly cleaving any component, reducing calcium-triggered vesicular release of acetylcholine at neuromuscular junctions
• The resulting attenuation of facial muscle contractile force is thought to diminish the repetitive skin folding that generates dynamic expression lines
• Because topically applied argireline penetrates the stratum corneum only minimally (less than ~0.2% of applied dose detected beyond the stratum corneum in ex vivo human skin studies), the magnitude and anatomical localisation of any in vivo neuromodulatory effect following topical application remain subjects of ongoing investigation

Pharmacokinetics (ADME)

PK–PD note: No formal systemic PK data identified for topical argireline. Ex vivo permeation studies in guinea pig and human skin showed that the vast majority (>99.7%) of applied dose is removed by washing; <0.2…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

5 registered trials — 0 currently recruiting.

NA
NCT06143033
A Clinical Trial to Evaluate the Effects of an Eye Serum on Improving the Appearance of the Periorbital Area

COMPLETED

Phase 1
NCT00942851
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

COMPLETED

NA
NCT02597777
Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

COMPLETED

Phase 3
NCT01381484
Argireline in Treatment of Periorbital Wrinkles

COMPLETED

EARLY_Phase 1
NCT03878381
Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream

COMPLETED

Summary (literature)

The Cosmetic Ingredient Review (CIR) Expert Panel assessed acetyl hexapeptide-8 and concluded it is safe as used in cosmetic formulations at concentrations up to approximately 0.005% in leave-on products, based on low percutaneous absorption (log P approximately -6.3, dermal pene…

WADA status

Not specifically listed on the 2026 WADA Prohibited List. Argireline is a topically applied cosmetic peptide with no identified performance-enhancing mechanism …

Dominant research route: Topical (TOP)

Human double-blind, placebo-controlled clinical trials (blepharospasm adjunct and wrinkle appearance) and open-label cosmetic serum evaluations; applied to facial/periorbital skin

Bioavailability: Cutaneous absorption is limited by high molecular weight (~889 Da) and hydrophilicity. A 2015 in vitro study (Kraeling et al.) found that after 24 h, only ~0.22% of the applied dose was recovered in human stratum corneum and ~0.54% in hairless guinea pig stratum corneum, with ~99.7% removed by washing; negligible penetration into viable epidermis/dermis was detected.

Dominant and essentially exclusive research route. Studied as a cosmetic topical intended to mimic the N-terminal SNAP-25 fragment and reversibly inhibit SNARE complex assembly. No head-to-head trials vs. botulinum toxin; an independent 2023 double-blind split-face trial (Henseler) found no statistically significant wrinkle reduction vs. vehicle.

In vitro Franz diffusion-cell penetration studies using excised hairless guinea pig and human skin from cosmetic O/W, W/O, and W/O/W emulsion vehicles

Bioavailability: Hoppel et al. (2015, Eur J Pharm Sci) showed W/O/W multiple emulsions significantly increased peptide penetration vs. simple W/O; water-rich vehicles outperformed oil-rich vehicles. Kraeling et al. (2015) reported <0.2% penetration past stratum corneum at 24 h. Iontophoresis produced an ~30-fold increase in permeation vs. passive diffusion.

Vehicle/formulation composition, not just peptide concentration, drives penetration. Label claims of 'contains argireline' or '10% argireline' do not convey dermal delivery. These studies characterize skin-barrier flux, not systemic bioavailability.

In vitro chromaffin-cell catecholamine-release assays and SNARE-complex competition experiments (no intact-tissue route; cellular pharmacology)

Bioavailability: Mechanism (reversible competitive inhibition of SNAP-25 incorporation into the SNARE complex, reducing catecholamine exocytosis) was demonstrated in cell culture; whether the peptide reaches the neuromuscular junction in vivo after topical application is unproven given the poor cutaneous penetration data.

Mechanistic studies support the proposed botulinum-toxin-mimetic rationale but do not establish that topically applied peptide reaches its intended synaptic target in meaningful concentrations.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $0.970 · median $1.09 · p75 $4.32 · 7 researched vendors

Legit, COA-backed band: $0.890–$1.13/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$9

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendor-reported purity of >99% (HPLC/MS) for research-grade acetyl hexapeptide-3/8 (Peptide Sciences). No independent third-party (Janoshik/MZ Biolabs) purity data specific to Argireline was located in public databases during this research.

Independent labs cited for this compound

No FDA recalls, market withdrawals, or safety alerts specific to Argireline (acetyl hexapeptide-8) were found in FDA enforcement databases as of the research date. Argireline is regulated as a cosmetic ingredient, not a drug, so it generally falls outside FDA drug-recall pathways.

Buyer red-flag checklist

• Argireline is a cosmetic ingredient, not an FDA-approved drug; no NDA/IND has been filed, so any therapeutic/efficacy claim is unsupported by FDA review.
• Methionine residue (Ac-EEMQRR-NH2) is vulnerable to oxidation during shelf life; Kluczyk et al. detected the oxidized form (methionine sulfoxide, +16 Da) alongside native Argireline in commercial cosmetic products — a measurable degradation/quality concern.
• Vendor-reported purity (>99% via HPLC/MS) is a first-party claim; no independent third-party (Janoshik/MZ Biolabs) COA specific to Argireline was located in public sources.
• Actual concentration of acetyl hexapeptide-8 in finished cosmetics can vary; a validated HILIC-PDA quantitation method (Panderi et al., 2021) was developed specifically because content verification in complex formulations is non-trivial.
• Research-peptide vendors selling acetyl hexapeptide-3/8 with 'research use only' disclaimers operate in the same enforcement climate as the USApeptide.com FDA Warning Letter (Feb 2025), which found such disclaimers do not exempt products from drug status when marketed with therapeutic claims.
• In vitro penetration studies show >99% of applied Argireline remains in the stratum corneum with negligible dermal penetration, raising questions about whether the active reaches its proposed target in meaningful concentrations — relevant to interpreting any 'purity/quality' claims about efficacy.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab-test aggregates (Janoshik, MZ Biolabs, Finnrick) reporting underdosing prevalence for Argireline were found. A published analytical study (Panderi et al., Molecules 2021) developed a HILIC-PDA quantitation method for acetyl hexapeptide-8 in cosmetics, with a limit of quantitation of 1.5 µg/mL (formulations) and 0.002% w/w (creams) — indicating that actual concentrations in finished cosmetics can vary and require verification. Kluczyk et al. identified Argireline alongside its oxidized form (methionine sulfoxide) in commercial cosmetic products, indicating shelf-life degradation is a measurable quality concern.

• FDA Import Alert 66-41 ('Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.') directs FDA field divisions to detain shipments identified as unapproved new drugs marketed in the U.S. Argireline is primarily a cosmetic ingredient and is not specifically named in this alert; however, if marketed with drug-type therapeutic claims (e.g., treatment of wrinkles/disease), products containing acetyl hexapeptide-8 could in principle be subject to detention under this alert. No Argireline-specific firm is listed on the alert's public charge sheet as of research date.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not prohibited. Acetyl hexapeptide-8 (Argireline) does not appear on the WADA 2026 Prohibited List. Topical cosmetic peptides used exclusively on skin are generally not prohibited; WADA's S0 (non-approved substances) and S2 (peptide hormones/growth factors) categories target performance-enhancing peptides, not cosmetic topical neuropeptides.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Affiliate/influencer-driven hype around 'botox in a bottle' framing
• Brand-concentrated discourse (The Ordinary dominates discussion)
• Self-reported anecdote with no controlled measurement
• TikTok trend amplification skews positive early adopter reports

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Synthetic hexapeptide (Ac-EEEMQRR-NH2) that competitively inhibits SNARE complex assembly to attenuate facial muscle contraction and reduce dynamic wrinkles. Approximately 21 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Cosmetic ingredient (OTC). Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet